In vitro transcription (IVT) mRNA is widely used in basic research and application which provides a promising gene expression system for rapid and controllable induction of target proteins. Based on its safety and high efficiency, IVT mRNA is a powerful approach with potential applications in regenerative medicine, vaccination, cell engineering, and protein replacement therapy. IVT mRNA synthesis with internal epigenetic modifications requires DNA template, enzymes, nucleotides, and buffer components. Not familiar with IVT mRNA technology or looking for a fast and effective service? Abnova provides fully mRNA synthesis service encompassing DNA template production, mRNA production and mRNA QC to fulfill customer demand. Our technical support is available to accommodate additional requests and needs required by your experiments.

Custom_IVT_mRNA.pdf

mRNA Synthesis Flowchart

 

Advantages
  • Customized mRNA from several hundred to thousands of bases
  • Optimized procedure of mRNA synthesis and purification
  • Cell-free production without toxic chemicals
  • Qualified RNA to match customer needs
  • Ready for most downstream applications
  • High-quality services with competitive prices
 
 

Specification

IVT Synthesis of mRNA Service Details

Services Items

Lead Time

DNA Template Production

Amplification of the gene of interest* and cloning it into the expression vector

 4 weeks

Plasmid DNA preparation and purification

mRNA Production

Linearized DNA preparation

4 Days

In vitro transcription of linearized DNA into RNA

RNA capping

Capped RNA purification and quantification**
mRNA QC

Integrity and purity: agarose gel electrophoresis of RNA

 2 Days
Protein expression: RNA transfection into cell and cell lysate subjected to Western blot analysis*** 2 Weeks
 

          Note：

          * Customers provide target sequence or DNA plasmid
          ** Adjustable amount of RNA yield to match customer demand
          *** Optional task depends on customer needs

 

 

Capping Methods

 

Capping methods
Co-transcriptional Modification
Sequence

RNA Sequence

 Capping sequence Cap Analog Features
Cap 0

GAUG

 3´-O-Me-m7G(5')ppp(5')GAUG Anti-Reverse
GTP competition
Cap 1

AUG

 m7G(5')ppp(5')(2'OMeA)pUG Without Anti-Reverse
Without GTP competition
Cap 1 AGG m7(3'OMeG)(5')ppp(5')(2'OMeG)pGG Anti-Reverse
Without GTP competition
Cap 1 GGG m7(3'OMeG)(5')ppp(5')(2'OMeA)pGG Anti-Reverse
GTP competition
Post-transcriptional Modification
 Sequence  RNA Sequence Capping sequence 
Cap 0 AUG
UUG
GUG
CUG		 m7G(5')ppp(5')AUG
m7G(5')ppp(5')UUG
m7G(5')ppp(5')GUG
m7G(5')ppp(5')CUG
Cap 1 AUG
UUG
GUG
CUG		 m7G(5')ppp(5')(2'OMeA)UG
m7G(5')ppp(5')(2'OMeA)UG
m7G(5')ppp(5')(2'OMeG)UG
m7G(5')ppp(5')(2'OMeC)UG
Cap 1 AGG
GGG
UGG
CGG		 m7G(5')ppp(5')(2'OMeA)GG
m7G(5')ppp(5')(2'OMeU)GG
m7G(5')ppp(5')(2'OMeG)GG
m7G(5')ppp(5')(2'OMeC)GG
Cap 1 AGG
UGG
GGG
CGG		 m7G(5')ppp(5')(2'OMeA)GG
m7G(5')ppp(5')(2'OMeU)GG
m7G(5')ppp(5')(2'OMeG)GG
m7G(5')ppp(5')(2'OMeC)GG
 
 

Nucleoside Modifications
  • Pseudouridine (Ψ)
  • 5-methylcytidine (m5C)
  • N1-methylpseudouridine (N1mΨ)
 
 

Cap0/Cap1 and Pseudouridine Modification Luciferase Signal

For any inquiry, please contact : OEM@abnova.com

Back to Overview